Press Release

Bridge Biotherapeutics implements Medidata technology to develop a novel therapy for idiopathic pulmonary fibrosis

Seoul, August 29, 2022 - Medidata, a Dassault Systèmes company, announced that Bridge Biotherapeutics is implementing Medidata’s cloud-based clinical solutions to optimize their clinical trial efficiency and manage clinical data by utilizing Rave EDC, Rave RTSM, and eCOA.

Bridge Biotherapeutics is digitalizing their phase II global clinical trial for their first-in-class candidate of Idiopathic pulmonary fibrosis (IPF), ‘BBT-877’, utilizing Medidata’s solution that expedites the new drug development process. FDA approved a phase II trial for BBT-877 last month. Medidata’s three solutions, Rave EDC, Rave RTSM, and Medidata eCOA, connect into one unified platform that can streamline data management workflow, mitigate risk, cut development costs, and secure data integrity.

“Idiopathic pulmonary fibrosis (IPF) is a fatal disease that results in death within 3-5 years of more than 50% of patients if not treated properly. We are strategically focusing on this disease area. BBT-877 is a first-in-class autotaxin inhibitor for IPF and will be a first milestone to initiate global business development, including license-out,” said Jeong-Gyu Lee, CEO of Bridge Biotherapeutics. “I strongly believe that implementing Medidata’s solutions into our clinical trial will help us increase clinical efficiency and meet global data compliance.”

Rave EDC is the unified clinical research platform that connects processes, eliminates data reconciliation, and delivers cross-functional and cross-study data insight. RTSM is entirely unified with Rave EDC with no customized integration, helps randomize patients, and provides Direct-to-Patient (DtP) capabilities to monitor supply management of clinical drugs without downtime. Medidata eCOA is built as part of the Medidata Clinical Cloud platform, a patient-oriented clinical outcome solution that collects objective patient data. Medidata eCOA provides a single-distribution model that streamlines its establishment workflow and helps collect accurate data from patients, caregivers, and physicians.

Jaegu Yoo, Vice President, Sales of Medidata Korea, said, “The Bridge Biotherapeutics clinical trials for idiopathic pulmonary fibrosis across eight countries, including South Korea and the United States, make it essential to manage an enormous amount of data with a systemic approach. We hope Medidata’s diverse and innovative solutions optimize the clinical trial operation workflow to develop this novel therapy, which has an unmet need in the IPF treatment.”

About Bridge Biotherapeutics
Bridge Biotherapeutics Inc. is a publicly traded clinical-stage biotech company based in the Republic of Korea with offices in the U.S. and China. Founded in 2015, Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics for disease indications with high unmet medical needs including cancer, ulcerative colitis, and fibrotic diseases. The company's clinical pipeline includes BBT-401, a first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis; BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF); and BBT-176, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with C797S triple EGFR mutations. Entering 2022, the company enhances its strategic focus on fibrotic diseases and cancers. For more information, visit https://www.bridgebiorx.com/en/

About Medidata
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 2,000+ customers and partners access the world's most trusted platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: FR0014003TT8, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata.

About Dassault Systèmes

Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production to achieve a more sustainable world for patients, citizens, and consumers.  Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com

3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systèmes, a French “société européenne” (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.